ストックスクリーナーアプリを入手
45.23
2.16%
0.80
Travere Therapeutics Inc (TVTX) 最新ニュース
Travere Therapeutics (TVTX) grants director 4,000 shares and 12,000 options - Stock Titan
Travere Therapeutics (TVTX) director receives stock and option awards - Stock Titan
[Form 4] Travere Therapeutics, Inc. Insider Trading Activity - Stock Titan
Travere Therapeutics (TVTX) director granted shares and 12,000 stock options - Stock Titan
Travere Therapeutics (TVTX) director granted shares and 12,000 options - Stock Titan
Travere Therapeutics (TVTX) grants director stock and options - Stock Titan
Travere Therapeutics (TVTX) investors back equity plan boost and all 2026 meeting items - Stock Titan
Travere Therapeutics Rides FILSPARI Surge After FDA Win - TipRanks
Insider Sell Alert: Timothy Coughlin Sells 3,250 Shares of Trave - GuruFocus
Travere Therapeutics (TVTX) director sells 3,250 shares in Rule 10b5-1 trade - Stock Titan
Stephens Investment Management Group LLC Acquires 121,955 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Bank of America Securities Remains a Buy on Travere Therapeutics (TVTX) - The Globe and Mail
(TVTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
Armistice Capital/Steven Boyd discloses 4,897,417 TVTX shares (5.27%) - Stock Titan
Why Travere Therapeutics Stock Is Tumbling Today - TipRanks
Travere, Ligand Pharma announce FDA label expansion for Filspari - MSN
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Travere Therapeutics launches first FDA-approved therapy for rare kidney disease FSGS. - Pluang
UBS Group AG Has $16.15 Million Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 12, 2026 - BioSpace
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
State of New Jersey Common Pension Fund D Takes Position in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Issues New Convertible Notes to Refinance Debt - TipRanks
Travere Therapeutics Completes $525 Million 0.50% Convertible Notes Offering Led by JPMorgan, Jefferies, Leerink - TradingView
[8-K] Travere Therapeutics, Inc. Reports Material Event - Stock Titan
RTRX6388605 Bond Coupon Analysis — Rate & Payments - TradingView
Travere prices upsized $475.0 million convertible senior notes offering to refinance 2029 convertible notes - MSN
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters - Yahoo Finance
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters - The Motley Fool
MSN Money - MSN
Travere Therapeutics analysts increase their forecasts following Q1 earnings - MSN
RTRX6388605 Bond Price and Chart — FINRA:RTRX6388605 - TradingView
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Travere (TVTX) Q4 2025 Earnings Transcript - AOL.com
Travere Therapeutics Insider Sold Shares Worth $1,092,657, According to a Recent SEC Filing - Moomoo
Travere Therapeutics to Participate at Upcoming Investor ConferencesMay 7, 2026 - BioSpace
Travere Therapeutics Inc SEC Filings - Stock Titan
Travere Therapeutics plans $400M convertible notes offering - MSN
Travere Therapeutics Prices Upsized $475 Million Debt Offering - Moomoo
Travere Therapeutics Insider Sold Shares Worth $988,875, According to a Recent SEC Filing - Moomoo
Travere Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:TVTX) 2026-05-07 - Seeking Alpha
[424B5] Travere Therapeutics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Travere Therapeutics (TVTX) Heads Into Q1 2026 With Sharply Narrowed Trailing Losses Testing Bull Case - Sahm
Travere Therapeutics Insider Sold Shares Worth $360,000, According to a Recent SEC Filing - Moomoo
Travere Therapeutics Insider Sold Shares Worth $1,015,086, According to a Recent SEC Filing - marketscreener.com
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes - BioSpace
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):